Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 18

1.

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib.

Bean J, Brennan C, Shih JY, Riely G, Viale A, Wang L, Chitale D, Motoi N, Szoke J, Broderick S, Balak M, Chang WC, Yu CJ, Gazdar A, Pass H, Rusch V, Gerald W, Huang SF, Yang PC, Miller V, Ladanyi M, Yang CH, Pao W.

Proc Natl Acad Sci U S A. 2007 Dec 26;104(52):20932-7. Epub 2007 Dec 18.

2.
3.

Challenges of detecting EGFR T790M in gefitinib/erlotinib-resistant tumours.

Jänne PA.

Lung Cancer. 2008 Jun;60 Suppl 2:S3-9. doi: 10.1016/S0169-5002(08)70099-0. Review.

PMID:
18513582
4.
5.

[A simple view on lung cancer biology: The EGFR pathway].

Ruppert AM, Wislez M, Poulot V, Lacave R, Antoine M, Cadranel J.

Rev Mal Respir. 2011 Apr;28(4):565-77. doi: 10.1016/j.rmr.2011.03.005. Epub 2011 Apr 13. Review. French.

PMID:
21549910
6.

Structural and mechanistic underpinnings of the differential drug sensitivity of EGFR mutations in non-small cell lung cancer.

Eck MJ, Yun CH.

Biochim Biophys Acta. 2010 Mar;1804(3):559-66. doi: 10.1016/j.bbapap.2009.12.010. Epub 2009 Dec 22. Review.

7.

Recent progress on third generation covalent EGFR inhibitors.

Cheng H, Nair SK, Murray BW.

Bioorg Med Chem Lett. 2016 Apr 15;26(8):1861-8. doi: 10.1016/j.bmcl.2016.02.067. Epub 2016 Feb 23. Review.

PMID:
26968253
8.

Epidermal growth factor receptor mutations in lung adenocarcinoma.

Siegelin MD, Borczuk AC.

Lab Invest. 2014 Feb;94(2):129-37. doi: 10.1038/labinvest.2013.147. Epub 2013 Dec 30. Review.

9.

Role of mesenchymal-epithelial transition amplification in resistance to anti-epidermal growth factor receptor agents.

Califano R, Morgillo F, De Mello RA, Mountzios G.

Ann Transl Med. 2015 Apr;3(6):81. doi: 10.3978/j.issn.2305-5839.2015.03.44. Review.

10.

Profile of rociletinib and its potential in the treatment of non-small-cell lung cancer.

Tran PN, Klempner SJ.

Lung Cancer (Auckl). 2016 May 18;7:91-97. doi: 10.2147/LCTT.S94337. eCollection 2016. Review.

11.

Diagnosis and therapy of oral squamous cell carcinoma.

Konkimalla VB, Suhas VL, Chandra NR, Gebhart E, Efferth T.

Expert Rev Anticancer Ther. 2007 Mar;7(3):317-29. Review.

PMID:
17338652
12.

Recent Development of the Second and Third Generation Irreversible EGFR Inhibitors.

Han W, Du Y.

Chem Biodivers. 2017 Jan 11. doi: 10.1002/cbdv.201600372. [Epub ahead of print] Review.

PMID:
28075527
13.

Toward precision medicine with next-generation EGFR inhibitors in non-small-cell lung cancer.

Yap TA, Popat S.

Pharmgenomics Pers Med. 2014 Sep 19;7:285-95. doi: 10.2147/PGPM.S55339. eCollection 2014. Review.

14.

Covalent EGFR Inhibitors: Binding Mechanisms, Synthetic Approaches, and Clinical Profiles.

Hossam M, Lasheen DS, Abouzid KA.

Arch Pharm (Weinheim). 2016 Aug;349(8):573-93. doi: 10.1002/ardp.201600063. Epub 2016 Jun 3. Review.

PMID:
27258393
15.

Structure and clinical relevance of the epidermal growth factor receptor in human cancer.

Kumar A, Petri ET, Halmos B, Boggon TJ.

J Clin Oncol. 2008 Apr 1;26(10):1742-51. doi: 10.1200/JCO.2007.12.1178. Review.

16.

Modulation of c-Met signaling and cellular sensitivity to radiation: potential implications for therapy.

Bhardwaj V, Cascone T, Cortez MA, Amini A, Evans J, Komaki RU, Heymach JV, Welsh JW.

Cancer. 2013 May 15;119(10):1768-75. doi: 10.1002/cncr.27965. Epub 2013 Feb 19. Review.

17.

Strategies to Overcome Bypass Mechanisms Mediating Clinical Resistance to EGFR Tyrosine Kinase Inhibition in Lung Cancer.

Husain H, Scur M, Murtuza A, Bui N, Woodward B, Kurzrock R.

Mol Cancer Ther. 2017 Feb;16(2):265-272. doi: 10.1158/1535-7163.MCT-16-0105. Review.

PMID:
28159915
18.

MET inhibition in lung cancer.

Menis J, Giaj Levra M, Novello S.

Transl Lung Cancer Res. 2013 Feb;2(1):23-39. doi: 10.3978/j.issn.2218-6751.2012.12.04. Review.

Supplemental Content

Support Center